Gyre Therapeutics (GYRE) Total Current Liabilities (2010 - 2026)

Gyre Therapeutics (GYRE) has 17 years of Total Current Liabilities data on file, last reported at $19.8 million in Q1 2026.

• Quarterly Total Current Liabilities rose 4.2% year-over-year to $19.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.8 million (up 4.2% YoY) and the FY2025 annual result came in at $18.3 million, down 6.3% from the prior year.
• Total Current Liabilities advanced to $19.8 million in Q1 2026 per GYRE's latest filing, from $18.3 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $20.0 million in Q4 2023 and bottomed at $1.6 million in Q3 2022.
• The 5-year median for Total Current Liabilities is $15.6 million (2024), against an average of $13.1 million.
• The widest annual swing landed in 2022, when Total Current Liabilities tumbled 90.47%; it then soared 725.35% in 2024.
• Tracing GYRE's Total Current Liabilities over 5 years: stood at $12.2 million in 2022, then surged by 63.76% to $20.0 million in 2023, then slipped by 2.65% to $19.5 million in 2024, then decreased by 6.3% to $18.3 million in 2025, then rose by 8.21% to $19.8 million in 2026.
• Per Business Quant, the three latest GYRE Total Current Liabilities figures stand at $19.8 million (Q1 2026), $18.3 million (Q4 2025), and $15.9 million (Q3 2025).

Peer Comparison